AIM:LID

Stock Analysis Report

Executive Summary

LiDCO Group Plc develops, manufactures, and sells hemodynamic monitoring equipment in the United Kingdom, the United States, Continental Europe, and internationally.

Snowflake

Fundamentals

Excellent balance sheet and overvalued.


Similar Companies

Share Price & News

How has LiDCO Group's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-2.5%

LID

0.2%

GB Medical Equipment

2.0%

GB Market


1 Year Return

-25.7%

LID

21.7%

GB Medical Equipment

3.3%

GB Market

Return vs Industry: LID underperformed the UK Medical Equipment industry which returned 21.7% over the past year.

Return vs Market: LID underperformed the UK Market which returned 3.3% over the past year.


Share holder returns

LIDIndustryMarket
7 Day-2.5%0.2%2.0%
30 Day-8.2%0.3%-1.0%
90 Day-12.4%7.8%-1.7%
1 Year-25.7%-25.7%24.3%21.7%8.3%3.3%
3 Year-43.3%-43.3%49.6%41.9%19.0%4.5%
5 Year-70.0%-70.0%100.1%82.6%38.4%8.4%

Price Volatility Vs. Market

How volatile is LiDCO Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is LiDCO Group undervalued based on future cash flows and its price relative to the stock market?

1.46x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Undervalued: LID (£0.04) is trading above our estimate of fair value (£0.02)

Significantly Undervalued: LID is trading above our estimate of fair value.


Price Based on Earnings

PE vs Industry: LID is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: LID is unprofitable, so we can't compare its PE Ratio to the UK market.


Price Based on Expected Growth

Low PEG Ratio: Insufficient data to calculate LID's PEG Ratio to determine if it is good value.


Price Based on Value of Assets

PB vs Industry: LID is good value based on its PB Ratio (1.5x) compared to the GB Medical Equipment industry average (2.8x).


Next Steps

Future Growth

How is LiDCO Group expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

80.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Earnings vs Savings Rate: LID is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: LID is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: LID is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: LID's revenue (13.2% per year) is forecast to grow faster than the UK market (4% per year).

High Growth Revenue: LID's revenue (13.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Estimates


Future Return on Equity

High Future ROE: LID is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has LiDCO Group performed over the past 5 years?

-72.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: LID is unprofitable, and losses have increased over the past 5 years at a rate of -72.5% per year.

Accelerating Growth: Unable to compare LID's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LID is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-4.5%).


Return on Equity

High ROE: LID has a negative Return on Equity (-29.71%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: LID is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: LID is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is LiDCO Group's financial position?


Financial Position Analysis

Short Term Liabilities: LID's short term assets (£5.7M) exceeds its short term liabilities (£2.2M)

Long Term Liabilities: LID has no long term liabilities


Debt to Equity History and Analysis

Debt Level: LID is debt free.

Reducing Debt: LID has not had any debt for past 5 years.


Balance Sheet

Inventory Level: LID has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if LID's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: LID has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if LID has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is LiDCO Group's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.0%markettop25%5.4%industryaverage1.5%forecastin3Years0%

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Notable Dividend: Unable to evaluate LID's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate LID's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if LID's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LID's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of LID's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

What is the CEO of LiDCO Group's salary, the management and board of directors tenure and is there insider trading?

4.2yrs

Average management tenure


CEO

Matt Sassone 0

4.2yrs

Tenure

UK£262,000

Compensation

Mr. Matthew Sassone, also known as Matt, has been the Chief Executive Officer of LiDCO Group plc since August 14, 2015. Mr. Sassone served as Senior Vice President of Global Marketing at ArjoHuntleigh AB.  ...


CEO Compensation Analysis

Compensation vs. Market: Matt's total compensation ($USD332.31K) is about average for companies of similar size in the UK market ($USD317.09K).

Compensation vs Earnings: Matt's compensation has been consistent with company performance over the past year.


Management Age and Tenure

4.2yrs

Average Tenure

Experienced Management: LID's management team is considered experienced (4.2 years average tenure).


Board Age and Tenure

2.8yrs

Average Tenure

62yo

Average Age

Experienced Board: LID's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUK£9,00027 Mar 19
Peter Grant
EntityIndividual
Role
Chairman of the Board
Non-Executive Chairman
Shares200,000
Max PriceUK£0.045
BuyUK£4,40027 Mar 19
Tim Hall
EntityIndividual
Role
Member of the Board of Directors
CFO, Company Secretary & Director
Shares100,000
Max PriceUK£0.044
BuyUK£4,40027 Mar 19
Philip Cooper
EntityIndividual
Role
Member of the Board of Directors
Non-Executive Director
Shares100,000
Max PriceUK£0.044

Ownership Breakdown


Management Team

  • Terry O'Brien (64yo)

    Co-Founder & Member of Clinical Advisory Board

    • Tenure: 0yrs
  • David Band

    Co-Founder

    • Tenure: 28.8yrs
  • Tim Hall (56yo)

    CFO, Company Secretary & Director

    • Tenure: 0.6yrs
  • Matt Sassone

    CEO & Director

    • Tenure: 4.2yrs
    • Compensation: UK£262.00k
  • Shane Doorish

    Head of North America

    • Tenure: 2.8yrs

Board Members

  • Terry O'Brien (64yo)

    Co-Founder & Member of Clinical Advisory Board

    • Tenure: 0yrs
  • Max Jonas

    Member of Clinical Advisory Board

    • Tenure: 0yrs
  • Peter Grant (63yo)

    Non-Executive Chairman

    • Tenure: 2.4yrs
    • Compensation: UK£45.00k
  • Michael Pinsky

    Member of Clinical Advisory Board

    • Tenure: 14yrs
  • Tim Hall (56yo)

    CFO, Company Secretary & Director

    • Tenure: 0.6yrs
  • Matt Sassone

    CEO & Director

    • Tenure: 4.2yrs
    • Compensation: UK£262.00k
  • Phil Cooper (55yo)

    Non-Executive Director

    • Tenure: 3.2yrs
    • Compensation: UK£30.00k
  • James Wetrich (62yo)

    Non-Executive Director

    • Tenure: 0.2yrs

Company Information

LiDCO Group Plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: LiDCO Group Plc
  • Ticker: LID
  • Exchange: AIM
  • Founded: 1991
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: UK£9.523m
  • Shares outstanding: 244.17m
  • Website: https://www.lidco.com

Number of Employees


Location

  • LiDCO Group Plc
  • 16 Orsman Road
  • London
  • Greater London
  • N1 5QJ
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
LIDAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPJul 2001
LDGDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJul 2001
LDRU.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJul 2001

Biography

LiDCO Group Plc develops, manufactures, and sells hemodynamic monitoring equipment in the United Kingdom, the United States, Continental Europe, and internationally. The company provides a range of closed  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/13 20:44
End of Day Share Price2019/10/11 00:00
Earnings2019/01/31
Annual Earnings2019/01/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)